Barclays raised the firm’s price target on Bristol Myers to $42 from $41 and keeps an Underweight rating on the shares. The analyst raised 2026 and 2027 Eliquis numbers in a post Inflation Reduction Act model update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Neurocrine price target raised to $189 from $177 at Jefferies
- Bristol Myers announces EMA validation to expand Brevanzi indication
- Healthcare Stocks Rise despite Medicare Price Cuts for Their Drugs
- Medicare-negotiated prices ‘benign’ for Bristol Myers, says Barclays
- Biden administration announces lower prices for 10 Medicare drugs in 2026